To lead the integration and growth of the SPECT business, SHINE has named Michael Rossi as CEO of SHINE SPECT USA, LLC.

Lantheus Holdings, Inc. ('Lantheus” or the 'Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better ...

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians ...

Since her diagnosis became public, Mette-Marit has reduced her official schedule and taken periods of medical leave, both due to feeling unwell and to side effects of her medicati ...

Background Axial spondyloarthritis (axSpA) impairs trunk strength, mobility and cardiorespiratory fitness. Despite exercise ...

Grant funding will advance pediatric lung and spine researchPHOENIX, Dec. 18, 2025 /PRNewswire/ -- Phoenix Children's ...

Redd’s daily treatment reveals how orangutans with chronic respiratory diseases are adapting to use certain medical tools ...

BioCardia®, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary ...

We present a case of a female in her late 40s with a 5-year history of well-managed type II diabetes mellitus, systemic hypertension and dyslipidaemia presented with acute severe abdominal pain, ...

The owner of a rescued lab dog considers if insights gleaned through animal research are enough to justify the practice.

In 2025, the medtech industry saw another year full of all kinds of deals in the mergers and acquisitions (M&A) arena.

In Luxor, the authority covered the cost of importing a specialized drug worth EGP 1.926 million to treat a child with severe pulmonary arterial hypertension, a rare condition that did not respond to ...